Betamethasone Valerate Cream

Betnovate Cream (Betamethasone Valerate Cream) - Product Information

Betnovate Cream (Betamethasone Valerate Cream) is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions.
Betnovate Cream is manufactured by GlaxoSmithKline Pharmaceuticals Limited, India in the strengths of 0.10% W/W and is available as a 20 gm tube.
We also have in stock Azelaic Acid Cream (Aziderm 10% and 20% Cream) which is which is topically administered for the treatment of bacterial skin infection such as acne and rosacea.

Name of the Drug

Betnovate Cream .

Manufacturer of Betnovate Cream

GlaxoSmithKline Pharmaceuticals Limited, India  
Website: www.gsk-india.com

Active Pharmaceutical Ingredient

The active ingredient present in Betnovate Cream is Betamethasone Valerate. Each gram of the cream contains contains 1.2 mg Betamethasone Valerate (equivalent to 1 mg Betamethasone).

Uses of Betnovate Cream (Betamethasone Valerate Cream)

Betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses. These include the following:
Atopic dermatitis (including infantile atopic dermatitis)
Nummular dermatitis (discoid eczema)
Prurigo nodularis
Psoriasis (excluding widespread plaque psoriasis)
Lichen simplex chronicus (neurodermatitis) and lichen planus
Seborrhoeic dermatitis
Irritant or allergic contact dermatitis
Discoid lupus erythematosus
Adjunct to systemic steroid therapy in generalised erythroderma
Insect bite reactions

Betnovate Cream (Betamethasone Valerate Cream) - Dosage

Betamethasone Valerate cream should be administered exactly as suggested by your doctor. Your doctor may recommend a dosage of Betnovate Cream depending on your age, medical requirement, body weight, other medical conditions, and current medications.
Apply thinly and gently rub in using only enough to cover the entire affected area once or twice daily for up to 4 weeks until improvement occurs, then reduce the frequency of application or change the treatment to a less potent preparation.
Betnovate creams are especially appropriate for moist or weeping surfaces and Betnovate ointments for dry, lichenified or scaly lesions, but this is not invariably so. Allow adequate time for absorption after each application before applying an emollient.
In the more resistant lesions, such as the thickened plaques of psoriasis on elbows and knees, the effect of betamethasone valerate can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response in such lesions; thereafter, improvement can usually be maintained by regular application without occlusion.
If the condition worsens or does not improve within 2 to 4 weeks, treatment and diagnosis should be re-evaluated.Therapy with Betamethasone Valerate should be gradually discontinued once control is achieved and an emollient continued as maintenance therapy.
Rebound of pre-existing dermatoses can occur with abrupt discontinuation of Betamethasone Valerate cream.
Betnovate Cream works effectively if the amount of Betamethasone is maintained at a constant level in the body. You should be systematic about the daily schedule for the medication such that you apply Betnovate Cream at about the same time every day, to get the maximum benefit of the medication. Continue using Betnovate Cream without missing any doses for the recommended treatment period and do not stop the treatment suddenly even if you feel better.

Please consult your doctor for exact dosing instructions. Betnovate Cream should be administered in the dose prescribed by the doctor and for the duration recommended by the doctor.

Missed Dose

If you forget to take your regular tablet dose on time, take it whenever you remember.
If you remember the next day, skip the missed dose and take your scheduled dose. Do not take a double dose to compensate the missed dose.

Betamethasone Valerate Cream Mechanism of Action

Betamethasone valerate cream works by reducing inflammation through its actions as a topical corticosteroid. It penetrates skin cells and binds to glucocorticoid receptors, which then enter the cell's nucleus to modify gene expression. This process suppresses the production of pro-inflammatory substances while increasing the production of anti-inflammatory proteins, thereby decreasing redness, swelling, and itching.

Storage Instructions for Betnovate Cream (Betamethasone Valerate Cream)

Store Betnovate Cream at controlled room temperature (20°C to 25°C),protected from heat, moisture, and sunlight. Excursions are permitted from 15°C to 30°C.
Retain the original packing of the medication and do not consume past its expiration date printed on the blister pack. Keep the pack of Betamethasone Valerate Cream away from the reach of children and pets. Do not dispose Betnovate Cream along with domestic waste or sewage. Consult your doctor or pharmacist about the correct method of disposal.

Contraindications

Betnovate Cream is contraindicated in patients with a hypersensitivity to Betamethasone Valerate or any inactive ingredient present in Betnovate Cream. Betamethasone valerate is contraindicated in dermatoses in infants under one year of age, including dermatitis.
The following conditions should not be treated with Betamethasone Valerate Cream:

• Untreated cutaneous infections
• Rosacea
• Acne vulgaris
• Pruritus without inflammation
• Perianal and genital pruritus
• Perioral dermatitis

Overdose

Topically applied Betamethasone Valerate may be absorbed in sufficient amounts to produce systemic effects. Acute overdosage is very unlikely to occur, however, in the case of chronic overdosage or misuse the features of hypercortisolism may occur.
In the event of overdose, Betamethasone Valerate Cream should be withdrawn gradually by reducing the frequency of application, or by substituting a less potent corticosteroid because of the risk of glucocorticosteroid insufficiency. Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

Warnings and Precautions

Local Hypersensitivity Reactions:
Local hypersensitivity reactions may resemble symptoms of the condition under treatment.
Hypercortisolism:
Manifestations of hypercortisolism (Cushing's syndrome) and reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, leading to glucocorticosteroid insufficiency, can occur in some individuals as a result of increased systemic absorption of topical steroids. If either of the above are observed, withdraw the drug gradually by reducing the frequency of application, or by substituting a less potent corticosteroid. Abrupt withdrawal of treatment may result in glucocorticosteroid insufficiency.
Paediatric Population:
In infants and children under 12 years of age, treatment courses should be limited to five days and occlusion should not be used; long-term continuous topical corticosteroid therapy should be avoided where possible, as adrenal suppression can occur.
Infection risk with occlusion
Bacterial infection is encouraged by the warm, moist conditions within skin folds or caused by occlusive dressings. When using occlusive dressings, the skin should be cleansed before a fresh dressing is applied.
Use in Psoriasis
Topical corticosteroids should be used with caution in psoriasis as rebound relapses, development of tolerances, risk of generalised pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin have been reported in some cases. If used in psoriasis careful patient supervision is important.
Application to the face
Prolonged application to the face is undesirable as this area is more susceptible to atrophic changes; therefore, treatment courses should be limited to five days and occlusion should not be used.
Application to the eyelids
If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as cataract and glaucoma might result from repeated exposure.
Visual disturbance
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Concomitant infection
Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and administration of appropriate antimicrobial therapy.
Chronic leg ulcers
Topical corticosteroids are sometimes used to treat the dermatitis around chronic leg ulcers. However, this use may be associated with a higher occurrence of local hypersensitivity reactions and an increased risk of local infection.
Flammability risk
Product contains paraffin. Instruct patients not to smoke or go near naked flames due to the risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it. Betnovate contains chlorocresol which may cause allergic reactions and cetostearyl alcohol which may cause local skin reactions (e.g. contact dermatitis).
Topical steroid withdrawal syndrome
Long term use of topical steroids can result in the development of rebound flares after stopping treatment (topical steroid withdrawal syndrome). A severe form of rebound flare can develop which takes the form of a dermatitis with intense redness, stinging and burning that can spread beyond the initial treatment area. It is more likely to occur when delicate skin sites such as the face and flexures are treated. Should there be a reoccurrence of the condition within days to weeks after successful treatment a withdrawal reaction should be suspected. Reapplication should be with caution and specialist advise is recommended in these cases or other treatment options should be considered.

Effects On Ability To Drive And Use Machines

There have been no studies to investigate the effect of Betnovate Cream (Betamethasone Valerate Cream) on driving performance or the ability to operate machinery.
A detrimental effect on such activities would not be anticipated from the adverse reaction profile of topical Betamethasone Valerate.

Side Effects of Betnovate Cream

The following local side effects are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

Betamethasone Valerate Cream During Pregnancy

Betamethasone Valerate Cream (Betnovate Cream) has been classified by the US FDA as Pregnancy Category C.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development.
The relevance of this finding to human beings has not been established; however, administration of Betnovate cream during pregnancy should only be considered if the expected benefit to the mother outweighs the risk to the foetus. The minimum quantity should be used for the minimum duration.
Do not use this medicine without your doctor's consent in case you are pregnant. Stop using this medication and inform your doctor immediately if you become pregnant during treatment.

Nursing Considerations

It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable amounts in breast milk. Administration of Betnovate cream during lactation should only be considered if the expected benefit to the mother outweighs the risk to the infant.
If used during lactation Betnovate cream should not be applied to the breasts to avoid accidental ingestion by the infant.
Do not use this medication without telling your doctor if you are breast-feeding a baby.

Buy Betnovate Cream 0.10% (Betamethasone Valerate Cream) Online From Only $2.20 per Tube

You can buy Betamethasone Valerate Cream online from Everest Online Pharmacy at a cheap price. Betnovate Cream 0.10%, manufactured by GlaxoSmithKline Pharmaceuticals Limited, India are supplied in a tube of 20 gm. The 20 gm tube cost only $2.20 per unit when you place an order for 50 tubes.

Disclaimer

The above information is provided to the best of our knowledge and in good faith. It is without a warrant of any kind, expressed or implied.

Shipping Restriction